دورية أكاديمية
Integrated miRNA Profiling of Extracellular Vesicles from Uterine Aspirates, Malignant Ascites and Primary-Cultured Ascites Cells for Ovarian Cancer Screening.
| العنوان: | Integrated miRNA Profiling of Extracellular Vesicles from Uterine Aspirates, Malignant Ascites and Primary-Cultured Ascites Cells for Ovarian Cancer Screening. |
|---|---|
| المؤلفون: | Skryabin GO; N.N. Blokhin National Medical Research Center of Oncology, 24 Kashirskoye Highway, Moscow 115522, Russia., Komelkov AV; N.N. Blokhin National Medical Research Center of Oncology, 24 Kashirskoye Highway, Moscow 115522, Russia., Zhordania KI; N.N. Blokhin National Medical Research Center of Oncology, 24 Kashirskoye Highway, Moscow 115522, Russia., Bagrov DV; Faculty of Biology, Lomonosov Moscow State University, 1-12 Leninskie Gory, Moscow 119991, Russia., Enikeev AD; N.N. Blokhin National Medical Research Center of Oncology, 24 Kashirskoye Highway, Moscow 115522, Russia., Galetsky SA; N.N. Blokhin National Medical Research Center of Oncology, 24 Kashirskoye Highway, Moscow 115522, Russia., Beliaeva AA; N.N. Blokhin National Medical Research Center of Oncology, 24 Kashirskoye Highway, Moscow 115522, Russia.; Faculty of Biology, Lomonosov Moscow State University, 1-12 Leninskie Gory, Moscow 119991, Russia., Kopnin PB; N.N. Blokhin National Medical Research Center of Oncology, 24 Kashirskoye Highway, Moscow 115522, Russia., Moiseenko AV; Faculty of Biology, Lomonosov Moscow State University, 1-12 Leninskie Gory, Moscow 119991, Russia., Senkovenko AM; Faculty of Biology, Lomonosov Moscow State University, 1-12 Leninskie Gory, Moscow 119991, Russia., Tchevkina EM; N.N. Blokhin National Medical Research Center of Oncology, 24 Kashirskoye Highway, Moscow 115522, Russia. |
| المصدر: | Pharmaceutics [Pharmaceutics] 2024 Jul 05; Vol. 16 (7). Date of Electronic Publication: 2024 Jul 05. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101534003 Publication Model: Electronic Cited Medium: Print ISSN: 1999-4923 (Print) Linking ISSN: 19994923 NLM ISO Abbreviation: Pharmaceutics Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI |
| مستخلص: | Extracellular vesicles (EVs) are of growing interest in the context of screening for highly informative cancer markers. We have previously shown that uterine aspirate EVs (UA EVs) are a promising source of ovarian cancer (OC) diagnostic markers. In this study, we first conducted an integrative analysis of EV-miRNA profiles from UA, malignant ascitic fluid (AF), and a conditioned medium of cultured ascites cells (ACs). Using three software packages, we identified 79 differentially expressed miRNAs (DE-miRNAs) in UA EVs from OC patients and healthy individuals. To narrow down this panel and select miRNAs most involved in OC pathogenesis, we aligned these molecules with the DE-miRNA sets obtained by comparing the EV-miRNA profiles from OC-related biofluids with the same control. We found that 76% of the DE-miRNAs from the identified panel are similarly altered (differentially co-expressed) in AF EVs, as are 58% in AC EVs. Interestingly, the set of miRNAs differentially co-expressed in AF and AC EVs strongly overlaps (40 out of 44 miRNAs). Finally, the application of more rigorous criteria for DE assessment, combined with the selection of miRNAs that are differentially co-expressed in all biofluids, resulted in the identification of a panel of 29 miRNAs for ovarian cancer screening. |
| References: | PLoS One. 2019 Nov 18;14(11):e0225249. (PMID: 31738788) Cell Rep. 2018 Oct 30;25(5):1346-1358. (PMID: 30380423) FEBS J. 2012 Jun;279(11):2047-59. (PMID: 22498306) Int J Mol Sci. 2021 Jul 29;22(15):. (PMID: 34360924) Oncol Lett. 2016 Jun;11(6):3911-3916. (PMID: 27313716) Front Oncol. 2020 Jul 21;10:1084. (PMID: 32850313) Cancer Biomark. 2019;24(1):31-42. (PMID: 30614794) Pathol Res Pract. 2023 Aug;248:154610. (PMID: 37307621) Biomedicines. 2021 Oct 10;9(10):. (PMID: 34680550) Front Oncol. 2020 Nov 26;10:535665. (PMID: 33324542) Cancer Manag Res. 2020 Feb 27;12:1483-1492. (PMID: 32161500) Mol Oncol. 2021 Dec;15(12):3659-3678. (PMID: 34160887) Oncol Lett. 2018 May;15(5):7571-7578. (PMID: 29725462) Lancet Oncol. 2006 Nov;7(11):925-34. (PMID: 17081918) Cancer Manag Res. 2021 Aug 21;13:6585-6597. (PMID: 34456588) Lancet Oncol. 2016 Aug;17(8):1137-1146. (PMID: 27402147) PLoS One. 2018 Nov 26;13(11):e0207319. (PMID: 30475821) Oncol Lett. 2021 Jan;21(1):23. (PMID: 33240429) Front Pharmacol. 2020 Jan 20;10:1500. (PMID: 32038230) Pathol Res Pract. 2023 Oct;250:154794. (PMID: 37683389) J Cell Physiol. 2019 Aug;234(10):16861-16872. (PMID: 30779342) Nanoscale Adv. 2021 Feb 16;3(7):1830-1852. (PMID: 36133088) Mol Immunol. 2012 Apr;50(4):278-86. (PMID: 22424315) J Exp Clin Cancer Res. 2021 Apr 30;40(1):148. (PMID: 33931086) Nat Cancer. 2023 Sep;4(9):1239-1257. (PMID: 37653142) Nanomedicine. 2020 Aug;28:102207. (PMID: 32334098) Micron. 2021 Jun;145:103044. (PMID: 33676158) Mol Cancer. 2010 Sep 03;9:232. (PMID: 20815877) Genome Biol. 2014;15(12):550. (PMID: 25516281) J Extracell Vesicles. 2024 Feb;13(2):e12404. (PMID: 38326288) Nat Rev Clin Oncol. 2018 Oct;15(10):617-638. (PMID: 29795272) Sci Rep. 2019 Mar 29;9(1):5335. (PMID: 30926864) Cancers (Basel). 2021 Mar 27;13(7):. (PMID: 33801595) Cancer Metastasis Rev. 2016 Jun;35(2):289-322. (PMID: 26970968) Nat Commun. 2015 Dec 21;6:10077. (PMID: 26687066) PLoS One. 2020 Jan 30;15(1):e0227949. (PMID: 31999742) Cancer Res. 2007 Sep 15;67(18):8699-707. (PMID: 17875710) Cells. 2020 Nov 16;9(11):. (PMID: 33207539) J Extracell Vesicles. 2015 Nov 11;4:28680. (PMID: 26563734) Cancers (Basel). 2020 Sep 09;12(9):. (PMID: 32916840) Nucleic Acids Res. 2015 Apr 20;43(7):e47. (PMID: 25605792) Extracell Vesicles Circ Nucl Acids. 2023;4(2):240-254. (PMID: 38288044) Cancers (Basel). 2019 Aug 10;11(8):. (PMID: 31405096) Adv Sci (Weinh). 2023 Sep;10(27):e2301930. (PMID: 37485618) Mol Cancer Res. 2015 Mar;13(3):393-401. (PMID: 25304686) Gene. 2015 Dec 15;574(2):330-6. (PMID: 26275944) Cell. 2019 Apr 4;177(2):428-445.e18. (PMID: 30951670) EBioMedicine. 2021 May;67:103365. (PMID: 33971402) PLoS One. 2013;8(2):e56647. (PMID: 23437196) Genes Immun. 2012 Dec;13(8):621-31. (PMID: 23034448) Gene. 2024 May 30;909:148265. (PMID: 38346459) J Extracell Vesicles. 2014 Mar 26;3:. (PMID: 24683445) Curr Protoc Cell Biol. 2006 Apr;Chapter 3:Unit 3.22. (PMID: 18228490) Medicine (Baltimore). 2023 Mar 3;102(9):e33085. (PMID: 36862865) J Cell Physiol. 2020 Apr;235(4):3320-3328. (PMID: 31549393) Br J Cancer. 2013 Aug 6;109(3):603-9. (PMID: 23868002) Nat Methods. 2012 Jun 28;9(7):676-82. (PMID: 22743772) BMC Cancer. 2014 Feb 11;14:80. (PMID: 24512620) Ann Oncol. 2017 Nov 01;28(suppl_8):viii61-viii65. (PMID: 29232466) Cancer Sci. 2020 Oct;111(10):3435-3444. (PMID: 32750177) Br J Cancer. 2020 Jul;123(1):9-16. (PMID: 32382112) Biochemistry (Mosc). 2022 Nov;87(11):1354-1366. (PMID: 36509726) Cell Commun Signal. 2023 Apr 13;21(1):77. (PMID: 37055761) J Mol Endocrinol. 2020 Jan;64(1):1-12. (PMID: 31710594) Oncogene. 2014 Jan 16;33(3):378-86. (PMID: 23318422) Wiley Interdiscip Rev RNA. 2021 May;12(3):e1635. (PMID: 33230974) Cell Death Dis. 2018 Apr 18;9(5):447. (PMID: 29670086) Sci Transl Med. 2018 Mar 21;10(433):. (PMID: 29563323) Oncotarget. 2014 Feb 28;5(4):944-58. (PMID: 24659709) Cells. 2022 Mar 22;11(7):. (PMID: 35406627) Bioinformatics. 2010 Jan 1;26(1):139-40. (PMID: 19910308) Int J Mol Sci. 2020 Sep 25;21(19):. (PMID: 32993038) Cancers (Basel). 2022 Jul 07;14(14):. (PMID: 35884376) Onco Targets Ther. 2019 Dec 16;12:11069-11082. (PMID: 31908476) J Cell Biochem. 2021 Jan;122(1):100-115. (PMID: 32951259) Oncogene. 2008 Aug 7;27(34):4712-23. (PMID: 18408758) Mol Clin Oncol. 2018 Jan;8(1):159-169. (PMID: 29387410) J Extracell Vesicles. 2015 May 14;4:27066. (PMID: 25979354) Dis Markers. 2020 Jan 14;2020:1075942. (PMID: 32025275) Oncotarget. 2016 Mar 29;7(13):16923-35. (PMID: 26943577) Front Cell Dev Biol. 2022 Oct 13;10:955486. (PMID: 36313570) Mol Carcinog. 2017 Aug;56(8):1992-1998. (PMID: 28370334) Source Code Biol Med. 2017 Feb 3;12:2. (PMID: 28174599) J Extracell Vesicles. 2018 Nov 23;7(1):1535750. (PMID: 30637094) Reprod Sci. 2022 Oct;29(10):2760-2767. (PMID: 34973152) Theranostics. 2019 Oct 18;9(26):8206-8220. (PMID: 31754391) Am J Physiol Gastrointest Liver Physiol. 2019 Nov 1;317(5):G670-G681. (PMID: 31369289) Mol Oncol. 2018 Nov;12(11):1935-1948. (PMID: 30107086) Cancers (Basel). 2021 May 18;13(10):. (PMID: 34069860) Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5331-6. (PMID: 24706848) J Ovarian Res. 2018 Mar 2;11(1):20. (PMID: 29499737) Int J Mol Sci. 2022 Apr 06;23(7):. (PMID: 35409396) PLoS One. 2021 Jul 28;16(7):e0255142. (PMID: 34320033) Nat Rev Mol Cell Biol. 2023 Jul;24(7):454-476. (PMID: 36765164) Cancer Lett. 2022 Aug 28;542:215735. (PMID: 35569696) Sci Transl Med. 2013 Jan 9;5(167):167ra4. (PMID: 23303603) Pathol Res Pract. 2023 Aug;248:154672. (PMID: 37413875) Gynecol Oncol. 2010 Oct;119(1):125-30. (PMID: 20624637) Best Pract Res Clin Obstet Gynaecol. 2017 May;41:139-152. (PMID: 28111228) Biomed Res Int. 2021 Oct 25;2021:6673655. (PMID: 34734085) Oncogene. 2010 Jun 17;29(24):3545-53. (PMID: 20400975) Oncol Rep. 2021 Feb;45(2):569-581. (PMID: 33416170) Cancer Biomark. 2018;22(1):79-87. (PMID: 29562498) Cells. 2021 Sep 01;10(9):. (PMID: 34571921) Best Pract Res Clin Obstet Gynaecol. 2017 May;41:3-14. (PMID: 27743768) Pathobiology. 2018;85(1-2):41-49. (PMID: 29020678) Int J Mol Sci. 2022 Oct 02;23(19):. (PMID: 36232981) |
| معلومات مُعتمدة: | 22-15-00373 Russian Science Foundation |
| فهرسة مساهمة: | Keywords: differential expression; extracellular vesicles; liquid biopsy; malignant ascites; miRNA; ovarian cancer; uterine aspirates |
| تواريخ الأحداث: | Date Created: 20240727 Latest Revision: 20240729 |
| رمز التحديث: | 20240729 |
| مُعرف محوري في PubMed: | PMC11280431 |
| DOI: | 10.3390/pharmaceutics16070902 |
| PMID: | 39065600 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1999-4923 |
|---|---|
| DOI: | 10.3390/pharmaceutics16070902 |